Lars Zender

Aug 10, 2024 | nature.com | Pauline Latzer |Florian Battke |Till-Karsten Hauser |Christian la Fougère |Uwe M. Martens |Deborah Blumenthal | +8 more

AbstractCurrent treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt.

Aug 7, 2024 | nature.com | Haoran Zhu |Masako Narita |Sarah Gough |Lars Zender |Sarah Aitken |Matthew Hoare | +2 more

AbstractOncogenic RAS-induced senescence (OIS) is an autonomous tumour suppressor mechanism associated with premalignancy1,2. Achieving this phenotype typically requires a high level of oncogenic stress, yet the phenotype provoked by lower oncogenic dosage remains unclear. Here we develop oncogenic RAS dose-escalation models in vitro and in vivo, revealing a RAS dose-driven non-linear continuum of downstream phenotypes.